<DOC>
	<DOCNO>NCT00038168</DOCNO>
	<brief_summary>Phase I : The goal clinical research study find high dose estramustine phosphate administer intravenously combination fix dose Taxol ( paclitaxel ) give safely participant prostate cancer fail benefit hormone treatment . Phase II : The goal clinical research study find combination drug estramustine phosphate paclitaxel shrink control prostate cancer respond hormone treatment . A second goal find side effect drug reverse . The safety drug also study .</brief_summary>
	<brief_title>Intravenous Estramustine With Taxol Hormone Refractory Prostate Adenocarcinoma</brief_title>
	<detailed_description>To determine maximum tolerate dose intravenous estramustine phosphate combine Taxol . To estimate complete partial response rate treatments intravenous estramustine phosphate combine Taxol treatment hormone-refractory adenocarcinoma prostate . To determine qualitative quantitative toxicity combination intravenous estramustine phosphate Taxol .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>Patients histologic proof adenocarcinoma prostate must fail conventional hormonal therapy . Patients must osteoblastic bone metastasis . At least one osteoblastic lesion must document plain film . Patients mixed osteolytic bone metastasis must biopsy exclude histologic variant prostate cancer metastasis another primary ( phase II ) . Patients must evidence progression disease demonstrate 2 consecutive rise PSA ( absolute change least 1 ng/mL ) 4 week . Patients flutamide , nilutamide , bicalutamide discontinue flutamide nilutamide bicalutamide least 4 week 8 week , respectively . Patients must expect survival least three month Zubrod performance status &lt; 2 ( Zubrod scale ; Appendix B ) . Patients may receive concurrent chemotherapy immunotherapy . Patients must castrate serum testosterone level ( &lt; 30 ng/dl ) . For patient medically castrate , lutenizing hormone release hormone analog must continue maintain testicular suppression . Patients must adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500/mm3 platelet count &gt; 100,000/mm3 ; adequate hepatic function define bilirubin &lt; 1.5 mg % SGOT ( AST ) &lt; 2X upper limit normal ; adequate renal function define serum creatinine clearance &gt; 40 cc/min ( measure calculate ) . Patients must &gt; = 18 year old . Patients may receive oral EMP one cytotoxic therapy . Patients must sign write informed consent form prior treatment . Patients severe intercurrent infection . Patients prior exposure Taxol . Patients whose tumor contain small cell sarcomatoid element . Patients evidence conduction block active myocardial ischemia ECG . Patients history prior malignancy ( except noninvasive cutaneous carcinoma ) . Patients history thromboembolism .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>